Colony-Stimulating Factors in the Prevention and Management of Infectious Diseases

Infectious Disease Clinics of North America

Volumn 25, Issue 4, 2011, Pages 803-817

  Page, Andrea V ^a   Liles, W Conrad ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cancer; Diabetic foot infection; Granulocyte colony stimulating factor; Granulocyte macrophage colony stimulating factor; Macrophage colony stimulating factor; Neutropenia; Pneumonia; Sepsis

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; COLONY STIMULATING FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER PATIENT; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; INFECTION PREVENTION; MORTALITY; MYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SINGLE DRUG DOSE; TREATMENT INDICATION; ZYGOMYCOSIS;

COMMUNICABLE DISEASES; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MONOCYTES; NEOPLASMS; NEUTROPENIA; NEUTROPHILS;

EID: 80455129199     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2011.07.007     Document Type: Review

References (86)

1. Hubel K., Dale D.C., Liles W.C. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-γ. J Infect Dis 2002, 185:1490-1501.
2. Lieschke G.J., Grail D., Hodgson G., et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994, 84:1737-1746.
3. Zhan Y., Basu S., Lieschke G.J., et al. Functional deficiencies of peritoneal cells from gene-targeted mice lacking G-CSF or GM-CSF. J Leukoc Biol 1999, 65:256-264.
4. Leavey P.J., Sellins K.S., Thurman G., et al. In vivo treatment with granulocyte colony-stimulating factor results in divergent effects on neutrophils functions measured in vitro. Blood 1998, 11:4366-4374.
5. Barth E., Fischer G., Schneider E.M., et al. Peaks of endogenous G-CSF serum concentrations are followed by an increase in respiratory burst activity of granulocytes in patients with septic shock. Cytokine 2002, 17:275-284.
6. Lejeune M., Sariban E., Cantinieaux B., et al. Defective polymorphonuclear leukocyte functions in children receiving chemotherapy for cancer are partially restored by recombinant human granulocyte colony-stimulating factor in vitro. J Infect Dis 1996, 174:800-805.
7. Crawford J., Dale D.C., Lyman G.H. Chemotherapy-induced neutropenia. Risks, consequences, and new directions for its management. Cancer 2004, 100:228-237.
8. Lyman G.H., Kuderer N.M., Crawford J., et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011, 117:1917-1927.
9. Kuderer N.M., Dale D.C., Crawford J., et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106:2258-2266.
10. Kuderer N.M., Dale D.C., Crawford J., et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007, 25:3158-3167.
11. Bohlius J., Herbst C., Reiser M., et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008, 4:CD003189.
12. Dekker A., Bulley S., Beyene J., et al. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006, 24:5207-5215.
13. Ringden O., Hassan Z., Karlsson H., et al. Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation 2010, 90:1022-1029.
14. Trivedi M., Martinez S., Corringham S., et al. Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant 2009, 43:895-908.
15. Sung L., Nathan P.C., Alibhai S.M., et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007, 147:400-411.
16. Wheatley K., Goldstone A.H., Littlewood T., et al. Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol 2009, 146:54-63.
17. Sasse E.C., Sasse A.D., Brandalise S.R., et al. Colony-stimulating factors for prevention of myelosuppressive therapy-induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev 2005, 3:CD004139.
18. Wang J., Zhan P., Ouyang J., et al. Prophylactic use of granulocyte colony-stimulating factor after induction chemotherapy in patients with newly diagnosed acute myeloid leukemia may increase the complete remission rate: a meta-analysis of five randomized controlled trials. Leuk Lymphoma 2009, 50:457-459.
19. Wang J., An L., Ouyang J., et al. Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis. Acta Haematol 2009, 121:223-226.
20. Heuser M., Zapf A., Morgan M., et al. Myeloid growth factors in acute myeloid leukemia: a systematic review of randomized controlled trials. Ann Hematol 2011, 90:273-281.
21. Gafter-Gvili A., Fraser A., Paul M., et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005, 142:979-995.
22. Herbst C., Naumann F., Kruse E.B., et al. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev 2009, 1:CD007107.
23. Timmer-Bonte J.N., de Boo T.M., Smit H.J., et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 2005, 23:7974-7984.
24. Lalami Y., Paesmans A., Aoun M., et al. A prospective randomized evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Support Care Cancer 2004, 12:725-730.
25. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
26. Aapro M.S., Bohlius J., Cameron D.A., et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur J Cancer 2011, 47:8-32.
27. Ribeiro D., Veldwijk M.R., Benner A., et al. Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion 2007, 47:969-980.
28. Wang B., Ludden T.M., Cheung E.N., et al. Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J Pharmacokinet Pharmacodyn 2001, 28:321-342.
29. Roskos L.K., Lum P., Lockbaum P., et al. Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006, 46:747-757.
30. Pinto L., Liu Z., Doan Q., et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007, 23:2283-2295.
31. Tan H., Tomic K., Hurley D., et al. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin 2011, 27:79-86.
32. Weycker D., Malin J., Kim J., et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 2009, 31:1069-1081.
33. Skarlos D.V., Timotheadou E., Galani E., et al. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. Oncology 2009, 77:107-112.
34. Gruschkus S.K., Lairson D., Dunn J.K., et al. Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy. J Am Geriatr Soc 2010, 58:1885-1895.
35. Clark O.A., Lyman G., Castro A.A., et al. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 2000, 4:CD003039.
36. Dale D.C., Bonilla M.A., Davis M.W., et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993, 81:2496-2502.
37. Dale D.C., Bolyard A.A., Schwinzer B.G., et al. The severe chronic neutropenia international registry: 10-year follow-up report. Support Cancer Ther 2006, 3:223-234.
38. Moore R.D., Keruly J.C., Chaisson R.E. Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med 1995, 155:1965-1970.
39. Ortega M., Almela M., Soriano A., et al. Bloodstream infections among human immunodeficiency virus-infected adult patients: epidemiology and risk factors for mortality. Eur J Clin Microbiol Infect Dis 2008, 27:969-976.
40. Pitrak D.L., Sutton S.H., Tsai H.C., et al. Reversal of accelerated neutrophil apoptosis and restoration of respiratory burst activity with r-metHuG-CSF (Filgrastim) therapy in patients with AIDS. AIDS 1999, 13:427-429.
41. Keiser P., Rademacher S., Smith J.W., et al. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients. Am J Med 1998, 104:48-55.
42. Levine A.M., Karim R., Mack W., et al. Neutropenia in Human Immunodeficiency Virus Infection. Data from the Women's Interagency HIV Study. Arch Intern Med 2006, 166:4405-4410.
43. Cooper C.L., Al-Bedwawi S., Lee C., et al. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006, 42:1674-1678.
44. Cooper C.L., Bedwawi S. Infection rates in HIV-HCV patients treated with interferon are similar to those in HCV mono-infection and not related to neutropenia. HIV Clin Trials 2006, 7:251-254.
45. Tajuddin T., Ryan E.J., Norris S., et al. Interferon-alpha suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR 7/8 agonist. J Gastroenterol Hepatol 2010, 25:1883-1890.
46. Koskinas J., Zacharakis G., Sidiropoulos J., et al. Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy. J Med Virol 2009, 81:848-852.
47. Koirala J., Gandotra S.D., Rao S., et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007, 14:782-787.
48. Zafrani L., Truffaut L., Kreis H., et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transplant 2009, 9:1816-1825.
49. Schmaldienst S., Bekesi G., Deicher R., et al. Recombinant human granulocyte colony-stimulating factor after kidney transplantation: a retrospective analysis to evaluate the benefit or risk of immunostimulation. Transplantation 2000, 69:527-531.
50. Turgeon N., Hovingh G.K., Fishman J.A., et al. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. Transpl Infect Dis 2000, 2:15-21.
51. Carr R., Modi N., Dore C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 2003, 3:CD003066.
52. Kuhn P., Messer J., Paupe A., et al. A multicentre, randomized, placebo-controlled trial of prophylactic recombinant granulocyte-colony stimulating factor in preterm neonates with neutropenia. J Pediatr 2009, 155:324-330.
53. Droemann D., Hansen F., Aries S.P., et al. Neutrophil apoptosis, activation and anti-inflammatory cytokine response in granulocyte colony-stimulating factor-treated patients with community-acquired pneumonia. Respiration 2006, 73:340-346.
54. Cheng A.C., Stephens D.P., Currie B.J. Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 2007, 2:CD004400.
55. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72.
56. Gerber A., Struy H., Weiss G., et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo neutrophil functions in nonneutropenic surgical intensive care patients. J Interferon Cytokine Res 2000, 20:1083-1090.
57. Weiss M., Voglic S., Harms-Schirra B., et al. Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission. Intensive Care Med 2003, 29:904-914.
58. Cheng A.C., Limmathurotsakul D., Chierakul W., et al. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin Infect Dis 2007, 45:308-314.
59. Stephens D.P., Thomas J.H., Dip G., et al. Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Crit Care Med 2008, 36:448-454.
60. Bo L., Wang F., Zhu J., et al. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care 2011, 15:R58.
61. Cruciani M., Lipsky B.A., Mengoli C., et al. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database Syst Rev 2009, 3:CD006810.
62. Berendt A.R., Peters E.J., Bakker K., et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev 2008, 24:S145-S161.
63. Pursell K., Verral S., Daraiesh F., et al. Impaired phagocyte respiratory burst responses to opportunistic fungal pathogens in transplant recipients: in vitro effect of r-metHuG-CSF (Filgrastim). Transpl Infect Dis 2003, 5:29-37.
64. Winston D.J., Foster P.F., Somberg K.A., et al. Randomized, placebo-controlled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients. Transplantation 1999, 68:1298-1304.
65. Schaefer H., Engert A., Grass G., et al. Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer. A randomized placebo-controlled clinical trial. Ann Surg 2004, 240:68-75.
66. Dranoff G., Crawford A.D., Sadelain M., et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary hemostasis. Science 1994, 264:713-716.
67. Stanley E., Lieschke G.J., Grail D., et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A 1994, 91:5592-5596.
68. Dale D.C., Liles W.C., Llewellyn C., et al. Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophils kinetics and function in normal human volunteers. Am J Hematol 1998, 57:7-15.
69. Heaney M.L., Toy E.L., Vekeman F., et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer 2009, 115:4839-4848.
70. Weycker D., Malin J., Barron R., et al. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol 2011, [Epub ahead of print].
71. Anaissie E.J., Vartivarian S., Bodey G.P., et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia. Am J Med 1996, 100:17-23.
72. Williams M.A., White S.A., Miller J.J., et al. Granulocyte-macrophage colony-stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients. J Infect Dis 1998, 177:107-115.
73. Rodriguez M.M., Calvo E., Marine M., et al. Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice. Antimicrob Agents Chemother 2009, 53:3569-3571.
74. Bandera A., Trabattoni D., Ferrario G., et al. Interferon-γ and granulocyte-macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis. Infection 2008, 36:368-373.
75. Lewis R., Hogan H., Howell A., et al. Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection. Leuk Lymphoma 2008, 49:163-165.
76. Meisel C., Schefold J.C., Pschowski R., et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression. Am J Respir Crit Care Med 2009, 180:640-648.
77. Rosenbloom A.J., Linden P.K., Dorrance A., et al. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest 2005, 127:2139-2150.
78. Presneill J.J., Harris T., Stewart A.G., et al. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002, 166:138-143.
79. Carr R., Brocklehurst P., Dore C.J., et al. Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomized controlled trial. Lancet 2009, 373:226-233.
80. Cruciani M., Mengoli C., Serpelloni G., et al. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis. Vaccine 2007, 25:709-718.
81. Sasaki M.G., Foccacia R., de Messias-Reason I.J. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003, 21:4545-4549.
82. Overton E.T., Kang M., Peters M.G., et al. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine 2010, 28:5597-5604.
83. Safdar A., Rodriguez G.H., Rueda A.M., et al. Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia. A prospective, randomized trial of safety and immunogenicity. Cancer 2008, 113:383-387.
84. Spearman P., Kalams S., Elizaga M., et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase 1 trial. Vaccine 2009, 27:243-249.
85. Hidaka T., Akada S., Teranishi A., et al. Mirimostim (macrophage colony-stimulating factor; M-CSF) improves chemotherapy-induced impaired natural killer cell activity, Th1/Th2 balance, and granulocyte function. Cancer Sci 2003, 94:812-820.
86. Ohno R., Miyawaki S., Hatake K., et al. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study. J Clin Oncol 1997, 15:2954-2965.